Bursitis

SAN FRANCISCO, Feb. 12, 2024 /PRNewswire/ -- Frozen shoulder, also known as adhesive capsulitis, is a condition characterized by pain and stiffness in the shoulder, resulting in difficulty of movement in the shoulder. It affects 2-5% of the population, typically those between 40 and 60 years of age. People with diabetes and hypothyroidism are at an increased risk. Even without treatment, frozen shoulder can get better with time; however, recovery may take up to three years. Pain medications and physical therapy (PT) are typically used as the main treatments, but there is little evidence supporting the use of PT. Study Comparing Frozen Shoulder Treatments A single-provider, randomized controlled trial (RCT) study presented at the 2024 Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS) used patient-reported outcome measures (PROMs) and health care costs to compare watchful waiting (WW) versus PT for the treatment and management of frozen shoulder. The study, " Watchful Waiting Achieves Higher Value Than Physical Therapy for the Treatment of Idiopathic Frozen Shoulder: A Prospective Randomized Controlled Trial," randomized 61 patients to either WW (31 patients) or PT (30 patients) and assessed outcomes at six weeks, three months, six months and 12 months. This is the first RCT to compare PT versus WW for frozen shoulder treatment using a value-based health care framework. The primary outcome was the American Shoulder and Elbow Surgeons Score (ASES), and secondary outcomes included the patient value (12-month ASES score divided by health care costs). The outcomes of the study include: WW and PT patients improved significantly at each time point for all PROMs (p<0.05 for all). There were no significant differences between WW and PT treatments at any point in time (p>0.05 for all). PT patients incurred 10 times higher costs than WW patients (normalized mean difference: 1,635.67; 95% CI: 967.19, 2,304.15; p<0.001) and achieved only 16.9% of the patient value (normalized mean difference: -146.97; 95%CI: -207.47, -86.47; p<0.001). Based on the findings of this study, physicians should inform their patients with adhesive capsulitis of the treatment options. These include non-operative management with medications, physical therapy, watchful waiting and surgery when indicated. Physicians may then decide on the most appropriate treatment plan for their patient which may include the patient's preferences and needs. # # # 2024 AAOS Annual Meeting Disclosure Statement About the AAOS With more than 39,000 members, the American Academy of Orthopaedic Surgeons is the world's largest medical association of musculoskeletal specialists. The AAOS is the trusted leader in advancing musculoskeletal health. It provides the highest quality, most comprehensive education to help orthopaedic surgeons and allied health professionals at every career level to best treat patients in their daily practices. The AAOS is the source for information on bone and joint conditions, treatments and related musculoskeletal healthcare issues; and it leads the healthcare discussion on advancing quality. Follow the AAOS on Facebook, X, LinkedIn and Instagram. SOURCE American Academy of Orthopaedic Surgeons

DUBLIN, June 2, 2023 /PRNewswire/ -- The "Global Musculoskeletal Partnering 2016-2023: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering. This report provides the full collection of musculoskeletal disease deals signed between the world's pharmaceutical and biotechnology companies since 2016. Trends in musculoskeletal partnering deals Financial deal terms for headline, upfront and royalty by stage of development Musculoskeletal partnering agreement structure Musculoskeletal partnering contract documents Top musculoskeletal deals by value Most active musculoskeletal dealmakers Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element. The report takes readers through the comprehensive musculoskeletal disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering musculoskeletal deals. The report presents financial deal terms values for musculoskeletal deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals. Report scope The report is intended to provide the reader with an in-depth understanding and access to musculoskeletal trends and structure of deals entered into by leading companies worldwide. Global Musculoskeletal Partnering 2016 to 2023 includes: Trends in musculoskeletal dealmaking in the biopharma industry since 2016 Access to headline, upfront, milestone and royalty data Access to hundreds of musculoskeletal deal contract documents Comprehensive access to over 600 musculoskeletal deal records The leading musculoskeletal deals by value since 2016 Most active musculoskeletal dealmakers since 2016 The report includes deals for the following indications: Arthritis, Ankylosing spondylitis, Juvenile arthritis, Osteoarthritis, Psoriatic arthritis, Rheumatoid arthritis, Bone fracture, Hip, Carpel tunnel syndrome, Frozen shoulder, Gout, Knee, Meniscus damage, Muscular dystrophy, Osteoporosis, Paget's disease, Spinal muscular atrophy, Bone pain, Back pain, Muscular pain, Stiffness, Weakness, plus other musculoskeletal indications. In Global Musculoskeletal Partnering 2016 to 2023, available deals and contracts are listed by: Headline value Upfront payment value Royalty rate value Stage of development at signing Deal component type Technology type Specific therapy indication Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The Global Musculoskeletal Partnering 2016-2023 report provides comprehensive access to available deals and contract documents for over 600 musculoskeletal deals. Analyzing actual contract agreements allows assessment of the following: What are the precise rights granted or optioned? What is actually granted by the agreement to the partner company? What exclusivity is granted? What is the payment structure for the deal? How are the sales and payments audited? What is the deal term? How are the key terms of the agreement defined? How are IPRs handled and owned? Who is responsible for commercialization? Who is responsible for development, supply, and manufacture? How is confidentiality and publication managed? How are disputes to be resolved? Under what conditions can the deal be terminated? What happens when there is a change of ownership? What sublicensing and subcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon? Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? Which jurisdiction does the company insist upon for agreement law? Key Topics Covered: Chapter 1 - Introduction Chapter 2 - Trends in musculoskeletal dealmaking 2.1. Introduction 2.2. Musculoskeletal partnering over the years 2.3. Musculoskeletal partnering by deal type 2.4. Musculoskeletal partnering by industry sector 2.5. Musculoskeletal partnering by stage of development 2.6. Musculoskeletal partnering by technology type 2.7. Musculoskeletal partnering by therapeutic indication Chapter 3 -Financial deal terms for musculoskeletal partnering 3.1. Introduction 3.2. Disclosed financials terms for musculoskeletal partnering 3.3. Musculoskeletal partnering headline values 3.4. Musculoskeletal deal upfront payments 3.5. Musculoskeletal deal milestone payments 3.6. Musculoskeletal royalty rates Chapter 4 - Leading musculoskeletal deals and dealmakers 4.1. Introduction 4.2. Most active in musculoskeletal partnering 4.3. List of most active dealmakers in musculoskeletal 4.4. Top musculoskeletal deals by value Chapter 5 - Musculoskeletal contract document directory 5.1. Introduction 5.2. Musculoskeletal partnering deals where contract document available Chapter 6 - Musculoskeletal dealmaking by therapeutic target 6.1. Introduction 6.2. Deals by musculoskeletal therapeutic target Companies Mentioned 3D-Side 3SBio A2A Pharmaceuticals Aavis Pharmaceuticals Abarca Abbvie AbCellera AC Bioscience Accenture Actigraph Activbody Active Implants Adaptive Health Additive Orthopaedics Advanced Human Imaging AdventHealth Affinia Therapeutics AGC Asahi Glass AgNovos Healthcare AgomAb Therapeutics Akashi Therapeutics AKL Research and Development AlfaMed Aligos Therapeutics AliMed Alkem Laboratories Allergan AlloSource Almirall Alpine Immune Sciences Altamira Bio Altasciences Alvogen Alvotech Ambry Genetics Amedica Amend Surgical American Association of Neuromuscular & Electrodiagnostic Medicine Amgen Amneal Pharmaceuticals AMRA AMRA Medical Anagenesis Biotechnologies Analysis Group AnaMar Angelini Pharma Angers University Anika Therapeutics ANI Pharmaceuticals Antares Pharma Antibe Therapeutics Apexigen Apple Apsen Farmacutica Aptahem Aptorum Group Aralez Pharmaceuticals Aratana Therapeutics Aravive Biologics argenx ARK Crystal Arrowhead Pharmaceuticals Arthrex Arthrosi Therapeutics Artialis Asahi Kasei Ascendis Pharma AskAt Asklepios Biopharmaceutical Assertio Therapeutics Astellas Pharma AstraZeneca Athrotech Atnahs Pharma Audentes Therapeutics Aurinia Pharmaceuticals Australian Research Council Autotelic BIO Avalere Health Avanos Medical Aveta Biomics AveXis Avidity Biosciences Avion Pharmaceuticals AWB Schraubtechnik und Industriebedarf Axovant Gene Therapies Azellon Cell Therapeutics Aziyo Biologics Back-A-Line Bacterin International Baebies Bamboo Therapeutics Bauerfeind Baxalta Bayer Baylor College of Medicine Bazis NN BC Platforms Beijing Tide Pharmaceutical Benitec Biopharma Berg BGI BillionToOne Bio-Thera Solutions BioAge Labs BioCanRx Biocomposites Biogen BioGen Medical Biohaven Pharmaceuticals BioInvent BioMarin Pharmaceutical BioMed X Innovation Center BionX Medical Technologies BioPharma Forest Bioqube Ventures Bioservo Technologies Biosolution Biosplice Bioventus BioVinc Bison & Rose Blue Belt Technologies Blueprint Medicines Bodycad Boehringer Ingelheim Bone Biologics Bone Therapeutics Brickell Biotech Brigham and Women's Hospital Bristol-Myers Squibb BRM Extremities BSN Medical Burke Therapeutics c-LEcta California Institute for Biomedical Research California Institute for Regenerative Medicine Calimmune Calliditas Therapeutics Camargo Pharmaceutical Services Camber Spine Technologies Can-Fite BioPharma CANbridge Pharmaceuticals Cantargia Capricor Therapeutics Capsigen CareFirst BlueCross BlueShield Carlsmed Carna BioSciences CartiHeal Cartiva CAS Casper Pharma Catabasis Pharmaceuticals Catalyst Pharmaceuticals cbdMD Cedars-Sinai Medical Center Celgene Celltech Cellthera Pharma Cell Therapy Catapult Celltrion Cellular Biomedicine Cel Sci Centinel Spine Centogene Cerhum For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

PALO ALTO, Calif., Aug. 22, 2022 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company announced that the first patient has been randomized in the clinical trial to evaluate anti-tumor necrosis factor (TNF) for patients with early-stage, pain predominant frozen shoulder. “Recruiting the first patient for the trial of anti-TNF therapy in frozen shoulder patients is a significant milestone,” said James Woody, M.D., Chief Executive Officer of 180 Life Sciences. “Treatment with anti-TNF at the early stage could improve pain and subsequently reduce disability for frozen shoulder patients.” 180 Life Sciences is supporting the study funded by the National Institute of Health and Care Research (NIHR) in the U.K. to investigate whether injections of anti-TNF during the early stages of frozen shoulder can reduce or prevent progression of the disease. The trial is sponsored by the University of Oxford and is led by Professor Nanchahal, consultant for 180 Life Sciences, together with his colleague Professor Sally Hopewell based at the Oxford Clinical Trials Research Unit, at the University of Oxford. 180 Life Sciences also has the rights for advancing these studies and commercialization of the trial results. Approximately 50% of patients with Dupuytren’s disease also have frozen shoulder and Professor Nanchahal has previously shown that that TNF, a pro-inflammatory protein, is a key driver of the fibrosis in early-stage Dupuytren’s disease.(1, 2) He led the successful phase 2a(3) and phase 2b(4) clinical trials of anti-TNF for Dupuytren’s disease. This frozen shoulder trial is a multicenter, randomized, double blind placebo controlled clinical trial to assess the feasibility of conducting a phase 3 clinical trial.(5). Prof Sir Marc Feldmann, FRS, Executive Co-chairman of the Company, who is widely recognized for his pioneering work leading up to the first successful use of anti-TNF for treating intractable rheumatoid arthritis, said “it is a pleasure to see 180 Life Sciences focusing on developing new uses for anti-TNF which has been one of the most successful drug classes of all time, and conducting clinical trials to fulfil unmet needs that anti-TNF can ameliorate.” About Frozen Shoulder Frozen shoulder, or adhesive capsulitis, is very common, affecting about 9% of adults.(6) The early stages are extremely painful and later stages are characterized by stiffness and limitation of motion, which gradually improves.(7) Current treatments include physical therapy and steroid injections, which have modest short-term benefits with no evidence of long-term benefit.(8, 9) Around 40% of patients have persistent stiffness 4 years after onset and may require surgery.(10) About 180 Life Sciences Corp. 180 Life Sciences Corp. is a clinical-stage biotechnology company driving ground-breaking studies into clinical programs which are seeking to address major unmet medical needs. The Company’s primary platform is a novel program to treat several inflammatory disorders using anti-TNF (tumor necrosis factor). About The National Institute for Health and Care Research (NIHR) The mission of the National Institute for Health and Care Research (NIHR) is to improve the health and wealth of the nation through research. We do this by: Funding high quality, timely research that benefits the NHS, public health and social care; Investing in world-class expertise, facilities and a skilled delivery workforce to translate discoveries into improved treatments and services; Partnering with patients, service users, carers and communities, improving the relevance, quality and impact of our research; Attracting, training and supporting the best researchers to tackle complex health and social care challenges; Collaborating with other public funders, charities and industry to help shape a cohesive and globally competitive research system; Funding applied global health research and training to meet the needs of the poorest people in low and middle income countries. NIHR is funded by the Department of Health and Social Care. Its work in low and middle income countries is principally funded through UK Aid from the UK government. Forward-Looking Statements This press release includes “forward-looking statements”, including information about management’s view of the Company’s future expectations, plans and prospects, within the safe harbor provisions provided under federal securities laws, including under The Private Securities Litigation Reform Act of 1995 (the “Act”). Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results and, consequently, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements and factors that may cause such differences include, without limitation, statements about the ability of our clinical trials to demonstrate safety and efficacy of our product candidates, and other positive results; the uncertainties associated with the clinical development and regulatory approval of 180 Life Science’s drug candidates, including potential delays in the enrollment and completion of clinical trials, issues raised by the FDA and MHRA, timing to complete required studies and trials, and timing to obtain governmental approvals; the potential that earlier clinical trials and studies may not be predictive of future results; 180 Life Sciences’ reliance on third parties to conduct its clinical trials, enroll patients, and manufacture its preclinical and clinical drug supplies; the ability to come to mutually agreeable terms with such third parties and partners, and the terms of such agreements; estimates of patient populations for 180 Life Sciences planned products; unexpected adverse side effects or inadequate therapeutic efficacy of drug candidates that could limit approval and/or commercialization, or that could result in recalls or product liability claims; 180 Life Sciences’ ability to fully comply with numerous federal, state and local laws and regulatory requirements, as well as rules and regulations outside the United States, that apply to its product development activities; the timing of filing, the timing of governmental review, and outcome of, planned Investigational New Drug (IND) applications for drug candidates; current negative operating cash flows and a need for additional funding to finance our operating plans; the terms of any further financing, which may be highly dilutive and may include onerous terms; statements relating to expectations regarding future agreements relating to the supply of materials and license and commercialization of products; the availability and cost of materials required for trials; the risk that initial drug results will not be able to be replicated in clinical trials or that such drugs selected for clinical development will not be successful; challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; the inherent risks in early stage drug development including demonstrating efficacy; development time/cost and the regulatory approval process; the progress of our clinical trials; our ability to find and enter into agreements with potential partners; our ability to attract and retain key personnel; changing market and economic conditions; our ability to produce acceptable batches of future products in sufficient quantities; unexpected manufacturing defects; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; expectations with respect to future performance, growth and anticipated acquisitions; the continued listing of the Company on The NASDAQ Stock Market; expectations regarding the capitalization, resources and ownership structure of the Company; expectations with respect to future performance, growth and anticipated acquisitions; the ability of the Company to execute its plans to develop and market new drug products and the timing and costs of these development programs; estimates of the size of the markets for its potential drug products; the outcome of current litigation involving the Company; potential future litigation involving the Company or the validity or enforceability of the intellectual property of the Company; global economic conditions; geopolitical events and regulatory changes; the expectations, development plans and anticipated timelines for the Company’s drug candidates, pipeline and programs, including collaborations with third parties; access to additional financing, and the potential lack of such financing; and the Company’s ability to raise funding in the future and the terms of such funding. These risk factors and others are included from time to time in documents the Company files with the Securities and Exchange Commission, including, but not limited to, its Form 10-Ks, Form 10-Qs and Form 8-Ks, and including the Annual Report on Form 10-K for the year ended December 31, 2021 and Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, and future SEC filings. These reports and filings are available at and are available for download, free of charge, soon after such reports are filed with or furnished to the SEC, on the “Investors”—“SEC Filings”—“All SEC Filings” page of our website at All subsequent written and oral forward-looking statements concerning the Company, the results of the Company’s clinical trial results and studies or other matters and attributable to the Company or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made, including the forward-looking statements included in this press release, which are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statement to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based, except as otherwise provided by law. Investors: Jason Assad Director of IR 180 Life Sciences Corp (678) 570-6791 Jason@180lifesciences.com Suzanne Messere Stern Investor Relations, Inc. (212) 698-8801 Suzanne.Messere@sternir.com L. S. Verjee et al., Unraveling the signaling pathways promoting fibrosis in Dupuytren's disease reveals TNF as a therapeutic target. Proceedings of the National Academy of Sciences of the United States of America110, E928-937 (2013). D. Izadi et al., Identification of TNFR2 and IL-33 as therapeutic targets in localized fibrosis. Science Advances5, eaay0370 (2019). J. Nanchahal et al., Anti-Tumour Necrosis Factor Therapy for Dupuytren's Disease: A Randomised Dose Response Proof of Concept Phase 2a Clinical Trial. EBioMedicine33, 282-288 (2018). J. Nanchahal et al., Anti-Tumour Necrosis Factor Therapy for Early Stage Dupuytren’s Disease (RIDD): a phase 2b randomised double blind, placebo-controlled trial. . Lancet Rheumatology 4 e407 - e416 (2022). S. Hopewell et al., Anti-TNF (adalimumab) injection for the treatment of adults with frozen shoulder during the pain predominant stage protocol for a multi-centre, randomised, double blind, parallel group, feasibility trial. NIHR Open Research2, 28 (2022). K. Walker-Bone, K. T. Palmer, I. Reading, D. Coggon, C. Cooper, Prevalence and impact of musculoskeletal disorders of the upper limb in the general population. Arthritis and Rheumatism51, 642-651 (2004). A. Rangan, N. Hanchard, C. McDaid, What is the most effective treatment for frozen shoulder? British Medical Journal354, i4162 (2016). R. Buchbinder, S. Green, J. M. Youd, Corticosteroid injections for shoulder pain. Cochrane Database Syst Rev, CD004016 (2003). M. J. Page et al., Manual therapy and exercise for adhesive capsulitis (frozen shoulder). Cochrane Database Syst Rev, CD011275 (2014). A. Rangan et al., Management of adults with primary frozen shoulder in secondary care (UK FROST): a multicentre, pragmatic, three-arm, superiority randomised clinical trial. Lancet396, 977-989 (2020).